Antimicrobial dosing considerations in obese adult patients (Q36892796)

16 August 2017

1 reference

title

Antimicrobial dosing considerations in obese adult patients (English)

1 reference

16 August 2017

0 references

Manjunath P Pai

1

1 reference

PubMed ID

17655508

16 August 2017

David T Bearden

series ordinal

2

1 reference

PubMed ID

17655508

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

16 August 2017

1 reference

16 August 2017

27

1 reference

16 August 2017

1081-1091

1 reference

16 August 2017

8

1 reference

Prevalence of overweight and obesity in the United States, 1999-2004

16 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Epidemic obesity and type 2 diabetes in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

21 January 2018

Obesity and infection

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Adipose tissue, adipokines, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Postoperative complications in obese and nonobese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

The origin of the "ideal" body weight equations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Drug disposition in obese humans. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Obesity and renal hemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

What is the best size descriptor to use for pharmacokinetic studies in the obese?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Prediction of the volume of distribution of a drug: which tissue-plasma partition coefficients are needed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Methods to assess tissue-specific distribution and metabolism of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Tissue penetration of cefpodoxime and cefixime in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Gentamicin serum concentrations: pharmacokinetic predictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Pharmacokinetics of nafcillin in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Population pharmacokinetics of linezolid in patients treated in a compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

Effect of Obesity on Gentamicin Pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1081

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.8.1081

1 reference

16 August 2017

1 reference

PubMed ID

17655508